LENZ Therapeutics Strategy and Business Model

Executive Overview

LENZ Therapeutics is a U.S.-based ophthalmology biopharmaceutical company focused on one large, clearly defined market: presbyopia, the age-related loss of near vision that affects most adults as they get older. The current public company took shape in 2024 through the merger of private LENZ Therapeutics with Graphite Bio, and it is headquartered in Solana Beach, California. LENZ’s strategy is unusually concentrated for a biotech company. Rather than pursuing a broad pipeline, it has centered its resources on aceclidine-based eye drops for presbyopia, led by LNZ100, with the goal of bringing a differentiated prescription option to eye-care professionals and patients who want an alternative to reading glasses and other corrective approaches. As of FY2024, LENZ remained pre-commercial and reported no product revenue. That makes the company’s business model forward-looking: success depends on regulatory execution, manufacturing readiness, launch preparation, and convincing prescribers that its clinical profile can support repeat use in a large lifestyle-oriented eye-care market. In practical terms, LENZ is trying to turn a single late-stage ophthalmic asset into a focused commercial franchise.

LENZ Therapeutics at a Glance

Logo
Common name	LENZ Therapeutics
Full legal name	LENZ Therapeutics, Inc.
Headquarters	Solana Beach, California, United States
Ownership	Public company
Ticker	LENZ
Exchange	NASDAQ
Market Cap	$181.39M
Revenue (FY2024)	#N/A
Founding / major historical milestones	The current public company was formed in 2024 through the merger of Graphite Bio and private LENZ Therapeutics; 2024 also marked pivotal Phase 3 data for LNZ100 and the company’s transition into a late-stage ophthalmology-focused public biotech.
Industry or industries	Biopharmaceuticals; ophthalmology; eye-care therapeutics
Key products or services	Development of prescription ophthalmic therapies for presbyopia, led by LNZ100; secondary aceclidine-based candidate LNZ101
Geographic footprint	Primarily United States as of FY2024, with U.S.-centric clinical, regulatory, and planned commercial focus
Business segments as officially reported	One operating and reportable segment
Company website	https://www.lenz-tx.com/

1. What Is the Strategy of LENZ Therapeutics?

LENZ’s public materials point to a focused specialty-biopharma strategy: develop and commercialize a differentiated pharmacologic treatment for presbyopia, concentrate capital on the highest-probability asset, and build a targeted U.S. ophthalmology franchise rather than a broad pipeline. Using the Playing to Win framework, the strategy can be framed as follows.

1. 1a. What is the winning aspiration of LENZ Therapeutics?

   LENZ’s winning aspiration appears to be to become a leading prescription company in presbyopia by bringing an aceclidine-based eye drop to market and building a durable commercial position in a very large, under-penetrated eye-care category. In management’s public framing, success is not just obtaining approval; it is establishing a product that eye-care professionals will prescribe and patients will refill because the efficacy, duration, and tolerability profile is compelling enough to compete with both existing prescription drops and non-drug substitutes such as reading glasses. A concrete near-term public objective has been regulatory advancement of LNZ100 after positive pivotal data.

2. 1b. Where does LENZ Therapeutics play?

   LENZ plays narrowly and deliberately. It is focused on presbyopia, an age-related near-vision condition, within ophthalmology. Its near-term commercial arena is the United States, where it can concentrate clinical, regulatory, market-access, and launch efforts around a single therapeutic area and a relatively concentrated set of optometrists and ophthalmologists who influence prescribing. LENZ is not trying to compete across the full ophthalmology market; it is choosing one large indication, one lead product candidate, and a specialty-commercial model.

3. 1c. How does LENZ Therapeutics plan to win?

   LENZ plans to win through product differentiation and focus. The company has publicly emphasized the profile of LNZ100 as a once-daily aceclidine-based approach designed to improve near vision while aiming to preserve functional distance vision and tolerability. In strategic terms, the company is betting that a better clinical experience can unlock repeat use in a market where many patients still default to readers or remain dissatisfied with earlier pharmacologic options. The second element of the win strategy is concentration: instead of spreading resources across many programs, LENZ has prioritized the asset with the clearest regulatory and commercial path.

4. 1d. What capabilities must LENZ Therapeutics have in place?

   To execute this strategy, LENZ needs strong capabilities in late-stage clinical development, regulatory affairs, ophthalmic chemistry, manufacturing, and controls, quality systems, and launch planning. Because it is a small company, it also needs skill in managing external partners such as contract research organizations, manufacturers, testing labs, and distribution providers. Commercially, it must build ophthalmology-focused medical affairs, market access, and a targeted field-sales capability. Financially, it needs disciplined capital allocation because a single-asset launch can create large fixed-cost commitments before revenue arrives.

5. 1e. What management systems does LENZ Therapeutics require?

   LENZ requires the management systems typical of a late-stage biopharma company moving toward commercialization: stage-gated portfolio review, development-governance processes, Good Manufacturing Practice and Good Clinical Practice compliance, pharmacovigilance and safety oversight, launch-readiness tracking, and tight cash-runway management. The company also needs metrics that connect clinical progress to commercial preparedness, including manufacturing validation milestones, regulatory submission readiness, target-prescriber coverage plans, reimbursement planning, and post-launch refill and persistence indicators once commercial sales begin.

2. What Are the Current Strategic Initiatives of LENZ Therapeutics?

Based on LENZ’s FY2024 public-company disclosures and related investor communications, the company’s current strategic initiatives are highly concentrated around making LNZ100 approvable, launchable, and commercially credible.

• Advance LNZ100 toward regulatory submission.Following positive Phase 3 CLARITY trial results in 2024, LENZ centered its program around LNZ100 as its lead asset. The practical work behind that decision includes assembling the regulatory package, completing chemistry, manufacturing, and controls requirements, and aligning clinical, safety, and quality documentation for a New Drug Application.
• Prioritize the lead asset and narrow portfolio spend.LENZ’s 2024 data readouts sharpened the company’s portfolio choices. Rather than funding parallel development broadly, LENZ has signaled that LNZ100 is the principal value driver. That is strategically important because it preserves capital and keeps management attention on the asset most likely to define the company’s future.
• Build commercial readiness ahead of launch.LENZ has been transitioning from a development-stage organization to a late-stage pre-commercial company. That typically includes work on physician segmentation, market research, pricing and reimbursement planning, medical affairs, patient services, distribution strategy, and specialty sales-force design. For a company like LENZ, launch preparation is not a side project; it is the bridge between clinical success and economic success.
• Secure manufacturing and supply reliability for a sterile ophthalmic product.Ophthalmic drug launches are sensitive to manufacturing quality, fill-finish execution, and release reliability. LENZ’s strategic agenda therefore includes commercial-scale supply planning, validation activities, and quality oversight of external manufacturing partners.
• Use the post-merger public-company platform to fund execution.The 2024 merger created a public listing and provided financial resources to support late-stage development and launch planning. For LENZ, balance-sheet stewardship is part of strategy: it must spend enough to be launch-ready while avoiding the type of overhead build that can pressure small biotech companies before revenue is established.

3. What Is the Business Model of LENZ Therapeutics?

As of FY2024, LENZ had no commercial revenue, so its business model is best understood as the model it is building rather than a mature revenue engine already in operation.

What customers actually buy

If approved and launched, customers would buy a prescription ophthalmic therapy intended to improve near vision in presbyopia. The end user is the patient, but demand creation depends heavily on eye-care professionals who diagnose, counsel, and prescribe.

Recurring or repeat-driven versus one-time

The model is inherently repeat-driven. Presbyopia is a chronic, age-related condition, so a successful therapy can generate recurring prescriptions if patients perceive meaningful benefit and acceptable tolerability. That makes persistence, refill behavior, and word-of-mouth among prescribers especially important.

How pricing power works

Pricing power would depend less on manufacturing cost and more on clinical differentiation, reimbursement support, and patient willingness to pay for convenience versus readers or contact lenses. In lifestyle-oriented ophthalmology categories, pricing can be constrained if insurance coverage is limited, so the real commercial question is often net price times refill rate, not list price alone.

Why the business mix matters

LENZ is currently a one-franchise story. That concentration raises both upside and risk. A successful launch would create a focused, high-gross-margin specialty-pharma business. A delay in approval, manufacturing, or uptake would matter disproportionately because there is no broad portfolio to absorb the shock.

What drives gross margin, operating margin, and cash generation

For a small-molecule ophthalmic product, gross margin could be attractive once scale is reached, because drug-product manufacturing costs are typically much lower than selling price. Operating margin, however, would be shaped by launch spending, medical affairs, field-sales investment, and gross-to-net deductions. Cash generation will likely remain negative until revenue scales, since regulatory, manufacturing, and commercial build-out costs arrive before repeat prescriptions become meaningful.

Revenue model

The core revenue model would be prescription-product sales through the pharmaceutical channel. Over time, LENZ could also pursue licensing or partnership revenue outside the United States, but as of FY2024 the central economic thesis remained direct commercialization of a lead U.S. ophthalmic product.

4. What Products and/or Services Does LENZ Therapeutics Sell?

As of FY2024, LENZ did not have an approved commercial product. Its value rests on a small number of late-stage ophthalmic product candidates.

• LNZ100LNZ100 is LENZ’s lead presbyopia candidate and the company’s most strategically important asset. Public disclosures in 2024 positioned it as the program the company intends to take forward commercially following positive pivotal data.
• LNZ101LNZ101 is another aceclidine-based presbyopia candidate. Based on LENZ’s 2024 portfolio focus, it appears strategically secondary to LNZ100 rather than the primary commercial vehicle.

There is no meaningful legacy-versus-growth split here. LENZ is essentially a pre-commercial company organized around one lead growth asset and a limited adjacent development program rather than a broad, diversified product portfolio.

5. What Are the Key Competitors or Peers of LENZ Therapeutics?

LENZ has a mix of direct pharmacologic competitors and non-drug substitutes. Because the company is focused specifically on presbyopia, the competitive set is narrower than for a broad ophthalmology company.

The competitive issue for LENZ is not just whether another company also has a presbyopia drop. It is whether LENZ can create a product profile strong enough to change patient and prescriber behavior in a category where doing nothing, using reading glasses, or choosing another optical correction are all viable alternatives.

6. What Is the Marketing Strategy of LENZ Therapeutics?

As of FY2024, LENZ’s marketing strategy was essentially a pre-launch strategy because it had not yet commercialized a product. That means the company’s most important “marketing” asset was clinical evidence, not advertising spend.

The likely marketing model is a focused specialty-pharma approach built around ophthalmologists and optometrists rather than broad mass-market promotion at the outset. In practical terms, that means physician education, scientific communication, launch messaging around the clinical profile of LNZ100, and evidence-based differentiation from earlier presbyopia drops and non-drug alternatives.

Direct-to-consumer awareness could become more relevant after approval because presbyopia is a consumer-recognized condition and many patients self-manage with reading glasses. But early commercialization appears more likely to depend on prescriber confidence, patient-selection clarity, and the ability to explain where the product fits in everyday practice. For LENZ, marketing is therefore a supporting capability tied tightly to medical affairs and commercial execution, not yet a brand-advertising machine.

7. What Are the Key Customer Segments of LENZ Therapeutics?

LENZ’s target market is concentrated rather than diversified. Its core customer ecosystem includes four groups.

• Adult presbyopia patients.This is the end-user population. These patients are typically middle-aged and older adults who want better near vision without relying entirely on readers or other correction methods.
• Optometrists and ophthalmologists.These clinicians are the crucial demand-shaping audience because they diagnose, evaluate suitability, and write prescriptions. In many ways, they are LENZ’s primary commercial customer even though they are not the final payer.
• Pharmacies, wholesalers, and channel intermediaries.These organizations matter because they determine product availability, inventory flow, and often the practical ease of prescription fulfillment.
• Payors and reimbursement decision-makers.Coverage can materially influence uptake and refill behavior. If reimbursement is limited, patient out-of-pocket economics become much more important.

From an end-market standpoint, LENZ is highly concentrated. It is not spread across many therapeutic areas, customer industries, or government channels. Its fortunes are tied largely to one eye-care condition and one prescriber community.

8. What Is the Sales Model of LENZ Therapeutics?

LENZ’s expected sales model is the classic U.S. specialty-pharma model for an ophthalmic prescription product, adapted to a presbyopia market that has both medical and consumer-like characteristics.

• Promotion to prescribers.LENZ is likely to use a targeted field-sales and medical-affairs model focused on eye-care professionals rather than a broad primary-care footprint. That allows efficient coverage of the prescriber base most likely to drive early uptake.
• Distribution through pharmaceutical channels.Product would typically move from manufacturer to wholesalers or specialty distribution partners, then to retail or specialty pharmacies, and finally to patients.
• Market access and patient support.Because prescription behavior can be sensitive to co-pay levels and reimbursement uncertainty, LENZ will likely need market-access planning and patient-support infrastructure to reduce friction at the point of fill.

This channel structure can help growth because a concentrated prescriber base makes field coverage more efficient. It also supports customer intimacy: a small company can stay close to key eye-care professionals. The tradeoff is that pricing and uptake are affected by gross-to-net dynamics, pharmacy execution, and reimbursement complexity, all of which matter disproportionately for a first product launch.

9. In What Geographies Does LENZ Therapeutics Operate?

As of FY2024, LENZ was primarily a U.S.-focused company. Its headquarters are in Solana Beach, California, and the company’s clinical, regulatory, and planned commercial efforts have been centered on the United States.

LENZ does not appear to operate a broad global commercial network or a large international manufacturing footprint of its own. Like many small biopharma companies, it relies on third parties for much of the operational work that sits behind development and supply. That means its physical footprint is relatively light even though its partner network may extend beyond one location.

Commercially, the most important geography is the U.S. eye-care market. Over time, ex-U.S. territories could become relevant through partnerships or licensing, but the company’s public strategy through FY2024 was clearly centered on establishing value in its home market first.

10. Who Are the Owners of LENZ Therapeutics?

LENZ is a publicly traded company on Nasdaq. Its ownership structure changed materially in 2024 when Graphite Bio and private LENZ Therapeutics combined and the merged company adopted the LENZ name. Following that transaction, former private LENZ securityholders became the majority owners of the combined company at closing, with the remainder held by legacy Graphite Bio shareholders and public-market investors.

As of the company’s FY2024 public disclosures, LENZ did not present itself as being controlled by a single shareholder. As with many development-stage biotech companies, beneficial ownership is primarily institutional and can shift over time through follow-on financings, public trading, and updated SEC ownership filings.

11. How Is LENZ Therapeutics Organized?

LENZ is organized as a focused, single-segment biopharmaceutical company. It is not structured as a conglomerate, multi-brand portfolio company, or regionally segmented operator.

At a practical level, the organization appears to revolve around a few core functions:

• Clinical development and regulatory affairs
• Chemistry, manufacturing, and controls and quality oversight
• Medical affairs and pre-commercial planning
• Corporate functions such as finance, legal, and public-company administration

Like many small biotech companies, LENZ uses an outsourced operating model for substantial portions of execution. That means the management structure is lean, while the effective delivery system includes external contract research organizations, manufacturers, laboratories, and other service partners. Officially, the company reports one operating and reportable segment, which is consistent with its narrow strategic focus.

12. How Does LENZ Therapeutics Operate?

LENZ operates like a late-stage, pre-commercial biotech company with a narrow pipeline and a high dependency on coordinated external execution. Day to day, the company’s value creation comes from moving a lead ophthalmic asset through the final steps of development, regulatory preparation, manufacturing readiness, and launch planning.

The most important operating activities include:

• Managing clinical data, regulatory interactions, and submission preparation
• Overseeing drug substance and drug product manufacturing for a sterile ophthalmic formulation
• Running quality systems, release testing, and compliance processes
• Protecting and managing intellectual property around the program
• Building the commercial infrastructure needed for a focused U.S. launch

The operational bottlenecks are typical of this stage of biotech development: manufacturing reliability, regulatory timing, the ability to scale external partners without losing control, and launch readiness. Because LENZ does not yet have a diversified revenue base, execution risk is concentrated. A delay in chemistry, manufacturing, and controls, a supply hiccup, or a slower-than-expected market-access rollout can have an outsized effect on the whole company.

13. What Are the Growth Opportunities for LENZ Therapeutics?

LENZ’s growth opportunities are substantial if LNZ100 clears the regulatory and commercial hurdles, but they are also tightly linked to one lead program.

• U.S. launch of LNZ100.The clearest growth opportunity is straightforward: convert positive late-stage data into approval and commercial adoption in the United States. Because presbyopia is highly prevalent, even modest penetration can create a meaningful revenue base.
• Expansion of pharmacologic treatment adoption.LENZ is not just competing for share within prescribed eye drops; it is also trying to expand the overall category by converting patients who currently rely only on reading glasses or do not seek treatment at all.
• Lifecycle management.If LNZ100 succeeds, LENZ could extend growth through line extensions, dosing refinements, additional formulations, or adjacent ocular programs that fit the same prescriber base.
• Ex-U.S. partnerships.A focused small biotech often uses partnerships to monetize geographies it does not intend to build direct infrastructure in. That could become a logical source of milestones, royalties, or lower-risk geographic expansion.
• Business development in ophthalmology.Once commercial footing is established, LENZ could become a platform for additional eye-care assets that leverage the same medical and sales infrastructure.

The constraints are equally clear: regulatory risk, manufacturing execution, physician adoption, patient refill behavior, reimbursement uncertainty, and the fact that LENZ is currently concentrated around one main product opportunity.

14. What Is the History of LENZ Therapeutics?

The current public LENZ Therapeutics is best understood as a transaction-created company rather than a long-standing operating company that simply listed its shares. Its present form emerged in 2024 through the merger of Graphite Bio, a publicly traded gene-editing company, and private LENZ Therapeutics, an ophthalmology company focused on presbyopia. After the merger, the combined company adopted the LENZ Therapeutics name and shifted the strategic center of gravity to eye care.

That history matters because it explains why LENZ looks different from many biotech companies. The company did not evolve gradually from a broad discovery engine into a diversified pipeline developer. Instead, it effectively used a public-company combination to accelerate access to capital and listing infrastructure for a focused ophthalmic program.

The defining milestone in 2024 was the advancement of LNZ100 through pivotal development and the publication of positive Phase 3 CLARITY data, which reinforced the company’s choice to center the business on a lead presbyopia asset. In that sense, LENZ’s history is short but strategically consequential: its public-market identity and its product strategy were both largely set in the same period.

15. What Are the Key Suppliers to LENZ Therapeutics?

Suppliers matter to LENZ because it is a small biopharma company that relies heavily on external partners rather than owning a large internal manufacturing and development network.

The most important supplier categories are:

• Active pharmaceutical ingredient suppliers for aceclidine and other formulation inputs
• Contract development and manufacturing organizations that formulate, fill, package, and scale sterile ophthalmic product
• Analytical testing and quality laboratories that support release testing, stability, and regulatory documentation
• Contract research organizations and clinical-site networks that support trials, data handling, and study operations
• Packaging and container-closure suppliers relevant to ophthalmic sterility, dosing consistency, and shelf-life performance

Supplier structure is strategically important because concentration risk can be high. A late-stage biotech with limited alternative sources can be exposed to delays in raw materials, fill-finish slots, batch failures, or quality observations. For LENZ, supplier management is not back-office procurement; it is part of the approval and launch equation.

16. How Does the Supply Chain of LENZ Therapeutics Function?

LENZ’s supply chain is that of a modern outsourced pharmaceutical company, with extra sensitivity because the product is a sterile ophthalmic solution. The chain begins with sourcing of active ingredient and excipients, then moves through formulation, sterile fill-finish, packaging, release testing, storage, and distribution into the pharmaceutical channel.

Several features make this supply chain strategically important:

• Sterility and quality control. Ophthalmic products demand tight manufacturing discipline because contamination or variability can create regulatory and patient-safety issues.
• Commercial-scale validation. Moving from clinical batches to launch supply is often a difficult transition for small biotech companies.
• Single- or limited-source exposure. Contract manufacturing relationships can become bottlenecks if capacity is tight or transfers are needed.
• Distribution reliability. Once launched, physician confidence can be hurt quickly if prescriptions are written but pharmacies cannot fill them smoothly.

For LENZ, the supply chain is less about global complexity than about reliability, compliance, and the ability to support a successful first launch without interruption.

17. What Is the R&D Strategy of LENZ Therapeutics?

LENZ’s research and development strategy is focused rather than exploratory. The company is not trying to build a broad discovery engine across multiple mechanisms and therapeutic areas. Instead, it has concentrated R&D spending on advancing aceclidine-based presbyopia programs, especially LNZ100, through late-stage development and toward commercialization.

That strategy has several implications:

• Clinical proof over platform breadth. LENZ is investing in development work intended to support approval and launch, not in a wide array of early research bets.
• Portfolio triage. The company’s choice to emphasize LNZ100 over LNZ101 after 2024 data reflects an R&D model that reallocates capital toward the strongest asset rather than protecting every program equally.
• Externalized execution. Much of the work is likely performed through partners, so LENZ’s internal R&D advantage lies in program judgment, design, oversight, and regulatory alignment.
• Potential lifecycle innovation. If the first product reaches market, R&D could shift toward formulation improvements, label expansion, or adjacent ophthalmic opportunities that fit the same franchise.

For LENZ, R&D is the central use of capital, but it is applied with a late-stage, commercialization-minded lens rather than a discovery-platform mindset.

18. What Is the Finance Strategy of LENZ Therapeutics?

LENZ’s finance strategy is typical of a late-stage biotech but especially important because the company is pre-revenue and concentrated around one lead asset. The main financial objective is to preserve enough capital to move LNZ100 through regulatory submission, manufacturing readiness, and launch preparation without taking on unnecessary fixed-cost burden too early.

At a high level, the finance strategy appears to rest on four principles:

• Runway preservation. Cash is a strategic asset, not just a balance-sheet item. LENZ must fund critical milestones while maintaining flexibility if timelines change.
• Focused capital allocation. Spending is directed toward the lead presbyopia program and the functions required to make it approvable and commercializable.
• Disciplined infrastructure build. The company needs enough commercial and operational capability to launch well, but not so much overhead that it weakens the balance sheet before revenue arrives.
• Future financing optionality. Like most development-stage biopharma companies, LENZ may need capital-market access, partnership capital, or both depending on launch timing and uptake.

There is no dividend or buyback story here. Finance strategy at LENZ is fundamentally about funding milestones, controlling burn, and sequencing investment to maximize the odds that one lead asset becomes a self-sustaining franchise.

19. What Major Acquisitions Has LENZ Therapeutics Made?

LENZ does not appear to be a serial acquirer. The pivotal transaction in its history was the 2024 merger between Graphite Bio and private LENZ Therapeutics, after which the combined company adopted the LENZ name and strategy. That transaction was transformational because it changed both the ownership structure and the underlying business focus of the public entity.

In other words, M&A has mattered to LENZ more as corporate formation and strategic repositioning than as a recurring acquisition program. As of FY2024, the company’s public strategy was centered on executing its lead presbyopia asset rather than pursuing a broad roll-up or portfolio-reshaping deal agenda.

20. How Companies Like LENZ Therapeutics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like LENZ Therapeutics engage Umbrex when they need that level of strategic and operational problem solving without hiring a full consulting team and its associated overhead. For a focused late-stage biopharma company, that can be especially useful during the transition from clinical development to commercialization. Umbrex consultants span Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI.

Representative projects Umbrex could support for a company like LENZ include:

• Launch readiness assessment for LNZ100, including workstreams across market access, field force design, patient services, supply readiness, and launch governance.
• Prescriber segmentation and targeting to identify which optometrists and ophthalmologists should be covered first and how call plans should vary by practice type and patient mix.
• Pricing, reimbursement, and gross-to-net strategy for a presbyopia therapy where patient affordability and payer behavior may heavily influence refill rates.
• Demand forecasting and commercial scenario planning to model uptake under different assumptions for coverage, cash-pay adoption, competition, and persistence.
• Commercial supply-chain risk review focused on ophthalmic manufacturing, fill-finish, release testing, inventory policy, and launch-contingency planning.
• Post-merger operating model design to define which capabilities should remain outsourced versus brought in-house as LENZ evolves from development-stage biotech to commercial company.
• Patient journey and message architecture to translate clinical data into clear, compliant value propositions for prescribers and patients.
• Medical-affairs and sales coordination model so scientific exchange, speaker programs, and field promotion reinforce one another without blurring roles.
• International partnering strategy to prioritize ex-U.S. territories, define deal structures, and support partner search for markets LENZ may not serve directly.
• Ophthalmology business-development screening to identify adjacent assets that could fit the same prescriber base after an initial launch and create a broader franchise over time.